ycf70 Antibody

What is JC70 antibody and what epitope does it recognize?

JC70 is a monoclonal antibody raised against a membrane preparation from a spleen affected by hairy cell leukemia. It recognizes a membrane-bound glycoprotein identical to that of the CD31 group of monoclonal antibodies . The antibody detects a fixation-resistant epitope on endothelial cells in both benign and malignant conditions, making it particularly valuable for studying vascular disorders in routinely processed tissue samples .

Unlike some other endothelial markers, JC70 demonstrates consistent staining of malignant endothelial cells in angiosarcomas, showing higher reliability than monoclonal or polyclonal antibodies to factor VIII-related antigen (FVIII-Rag) . This makes it an important tool for pathologists working with vascular tumors and related conditions.

How does JC70 antibody compare with other endothelial markers in research applications?

In comparative studies, JC70 has demonstrated superior consistency in staining malignant endothelial cells in angiosarcomas compared to factor VIII-related antigen (FVIII-Rag) antibodies . This is particularly significant for research involving vascular tumors where reliable endothelial cell identification is critical.

For Kaposi's sarcoma specifically, JC70 demonstrates selective staining of malignant endothelial cells but not spindle cells , providing important differential diagnostic capability. This selectivity makes JC70 valuable for distinguishing between different cell populations within complex tumor microenvironments.

When designing research panels for vascular pathology, JC70 should be considered alongside other endothelial markers as part of a comprehensive approach, particularly when working with formalin-fixed, paraffin-embedded tissues where many epitopes may be compromised.

What are the optimal conditions for using JC70 antibody in immunohistochemistry with paraffin-embedded tissues?

For optimal immunohistochemical staining with JC70 antibody in paraffin-embedded tissues, researchers should follow these methodological steps:

• Tissue preparation: Use standard formalin fixation and paraffin embedding protocols. JC70 recognizes a fixation-resistant epitope, offering an advantage over antibodies that lose reactivity after routine fixation .

• Antigen retrieval: Though the epitope is fixation-resistant, mild antigen retrieval may enhance staining. Heat-induced epitope retrieval in citrate buffer (pH 6.0) is recommended.

• Blocking step: As emphasized in the flow cytometry workflow (result ), blocking is essential to prevent non-specific antibody binding. Use 5% BSA or appropriate serum from the same species as the secondary antibody.

• Primary antibody incubation: Dilute JC70 according to manufacturer recommendations (typically 1-5 μg/ml) and incubate for 60 minutes at room temperature or overnight at 4°C.

• Washing: Include multiple wash steps to remove unbound antibody reagents that could yield misleading results . Use PBS with 0.05% Tween-20.

• Detection system: Use an appropriate detection system compatible with the host species of JC70. Both direct and indirect detection methods can be employed, with indirect methods providing signal amplification for less abundant targets .

How should controls be designed when using JC70 antibody for endothelial cell research?

Proper control design is critical for validating JC70 antibody results:

• Positive tissue controls: Include tissues known to express CD31, such as tonsil or normal blood vessels. This confirms the antibody's ability to detect the target epitope under your experimental conditions.

• Negative tissue controls: Include tissues known to lack CD31 expression to verify specificity.

• Antibody controls:

  • Isotype control: Include parallel sections stained with an isotype-matched control antibody at the same concentration to identify potential non-specific binding .

  • Secondary antibody-only control: Omit primary antibody but include all other steps to identify background from the detection system.

• Absorption controls: Pre-absorb JC70 with purified CD31 antigen before staining to demonstrate specificity of binding.

• Comparative controls: When studying vascular tumors, include staining with other endothelial markers (such as FVIII-Rag) to compare detection patterns, as JC70 has shown more consistent staining of malignant endothelial cells in angiosarcomas .

What are common issues with JC70 antibody staining and how can they be resolved?

Common issues with JC70 antibody staining and their solutions:

• Weak or absent staining:

  • Verify antibody concentration and incubation time

  • Implement more rigorous antigen retrieval methods

  • Check storage conditions of the antibody for potential degradation

  • Confirm tissue fixation method is compatible with the antibody

  • Consider using an amplification system for signal enhancement

• High background staining:

  • Increase blocking time and concentration

  • Implement Fc receptor blocking for tissues rich in immune cells

  • Reduce primary and secondary antibody concentrations

  • Include additional washing steps with increased duration

  • Use more specific secondary antibodies with cross-adsorption against sample species

• Inconsistent staining across samples:

  • Standardize tissue processing protocols

  • Control fixation time across all samples

  • Use automated staining platforms if available

  • Prepare fresh antibody dilutions for each experiment

  • Include positive control tissues in each staining batch

How can researchers validate the specificity of JC70 antibody in their experimental systems?

To validate JC70 antibody specificity in your experimental system:

• Multiple detection methods: Compare results from immunohistochemistry, immunofluorescence, and flow cytometry to confirm consistent target recognition.

• Correlation with gene expression: Confirm CD31 expression levels using RT-PCR or RNA-seq in the same samples to correlate with protein detection levels.

• Knockdown/knockout validation: If possible, use tissues or cells with CD31 knockdown/knockout to confirm absence of staining with JC70.

• Mass spectrometry validation: Perform immunoprecipitation with JC70 followed by mass spectrometry to confirm the identity of the pulled-down protein.

• Comparative antibody analysis: Test multiple CD31 antibodies targeting different epitopes and compare staining patterns.

• Western blot analysis: Confirm the molecular weight of the detected protein matches CD31.

As noted in search result : "It is essential to validate antibody performance in your own experimental system" regardless of reported specificities.

Can JC70 antibody be used effectively in multiplexed immunohistochemistry with other vascular markers?

JC70 antibody can be effectively incorporated into multiplexed immunohistochemistry panels with other vascular markers, with important methodological considerations:

• Antibody pairing strategy: When designing multiplex panels, select primary antibodies from different host species to prevent cross-reactivity of secondary antibodies . If using multiple mouse antibodies, consider sequential staining with intermediate blocking or use isotype-specific secondary antibodies.

• Epitope compatibility: Test compatibility of antigen retrieval methods for all antibodies in the panel. JC70's fixation-resistant epitope may allow flexibility in this regard.

• Visualization systems: For chromogenic multiplex IHC, use distinct chromogens for each antibody (e.g., DAB, AP-Red, etc.). For fluorescent multiplex, select fluorophores with minimal spectral overlap and include proper controls for autofluorescence.

• Complementary markers: Consider pairing JC70 (CD31) with:

  • ERG (nuclear endothelial marker)

  • CD34 (vascular endothelial marker)

  • D2-40 (lymphatic endothelial marker)

  • VEGFR2 (angiogenesis marker)

  • Factor VIII-Rag (comparison of malignant endothelial cell detection)

• Signal separation: If using tyramide signal amplification (TSA) systems, optimize concentration and incubation times to prevent signal bleed-through between channels.

• Validation approach: Validate multiplex protocols against single-marker controls on serial sections to ensure antibody performance is maintained in the multiplex setting.

What are the emerging applications of JC70 antibody in circulating tumor cell and liquid biopsy research?

Emerging applications of JC70 antibody in circulating tumor cell (CTC) and liquid biopsy research include:

• Identification of endothelial-derived CTCs: JC70 can help distinguish CTCs of endothelial origin, particularly from angiosarcomas and other vascular tumors where CD31 expression is maintained.

• Studying vasculogenic mimicry: Research into tumor cells that acquire endothelial-like characteristics (vasculogenic mimicry) can benefit from JC70's specificity for endothelial markers.

• CTC enrichment strategies: Negative selection approaches using JC70 to remove endothelial cells from blood samples can improve CTC isolation purity.

• Methodological approaches:

  • Flow cytometry-based detection using JC70 in combination with other markers

  • Microfluidic capture systems coated with JC70 for selective cell isolation

  • Immunomagnetic separation using JC70-conjugated beads

  • Immunofluorescence identification of CTCs in enriched blood samples

• Clinical correlations: JC70-based detection of endothelial CTCs may serve as a biomarker for monitoring treatment response in vascular tumors and potentially as a prognostic indicator.

How should researchers quantify and report JC70 immunohistochemistry results in vascular tumor research?

Quantification and reporting of JC70 immunohistochemistry in vascular tumor research should follow these methodological approaches:

• Scoring systems:

  • Intensity scoring: Use a 0-3 scale (0=negative, 1=weak, 2=moderate, 3=strong)

  • Proportion scoring: Estimate percentage of positive tumor cells (0-100%)

  • H-score calculation: Multiply intensity by proportion for a score of 0-300

  • Microvessel density (MVD): Count JC70-positive vessels in hotspot areas (typically 3-5 fields at 200× magnification)

• Digital image analysis:

  • Use validated image analysis software for unbiased quantification

  • Set consistent thresholds for positive staining across all samples

  • Report both intensity and area/proportion of positive staining

  • Consider spatial distribution of staining in heterogeneous tumors

• Reporting standards:

  • Specify antibody clone, dilution, and detection system

  • Document the scoring method with clear definitions

  • Include representative images of different staining intensities

  • Report both raw data and summarized results

  • Include intra- and inter-observer variability assessment

• Comparative analysis:

  • When comparing JC70 with other endothelial markers like FVIII-Rag, use the same quantification method for all markers

  • Report concordance and discordance between markers in the same tissue regions

  • Consider using correlation coefficients to quantify relationships between different markers

How can researchers address contradictory results between JC70 and other endothelial markers in their studies?

When faced with contradictory results between JC70 and other endothelial markers:

• Technical validation:

  • Repeat staining with freshly prepared antibody dilutions

  • Test multiple antibody lots to rule out lot-specific issues

  • Verify fixation and processing conditions are optimal for all markers

  • Include additional positive control tissues known to express all markers

• Biological interpretation:

  • Recognize that discrepancies may reflect biological differences in epitope expression rather than technical failures

  • Consider that JC70 has shown more consistent staining of malignant endothelial cells in angiosarcomas than FVIII-Rag

  • Evaluate if differences correspond to specific tumor regions, stages, or differentiation states

  • Determine if discrepancies correlate with clinical outcomes

• Molecular correlation:

  • Perform RNA-seq or qPCR to correlate protein expression with mRNA levels

  • Use laser capture microdissection to isolate specific cell populations for molecular analysis

  • Consider single-cell sequencing approaches to characterize heterogeneity

• Reporting recommendations:

  • Document all discrepancies transparently in research reports

  • Provide comprehensive details of all technical variables

  • Present multiple interpretations of contradictory findings

  • Discuss implications for diagnostic accuracy and research reproducibility

• Resolution strategies:

  • Use additional orthogonal markers to resolve discrepancies

  • Implement multiplex staining to visualize co-expression patterns

  • Consider functional assays to correlate marker expression with endothelial characteristics

  • Consult with pathologists specializing in vascular tumors for expert interpretation

How can JC70 antibody be integrated into emerging single-cell analysis technologies?

Integration of JC70 antibody into single-cell analysis technologies involves several methodological considerations:

• Single-cell suspension preparation:

  • Optimize tissue dissociation protocols that preserve CD31 epitopes

  • Include live/dead staining to exclude non-viable cells

  • Implement gentle dissociation methods to maintain surface protein integrity

  • Consider cryopreservation compatibility for batch processing

• Mass cytometry (CyTOF) integration:

  • Metal-conjugate JC70 antibody with lanthanide metals for CyTOF analysis

  • Validate metal-conjugated JC70 against conventional fluorescent versions

  • Optimize antibody concentration to prevent signal spillover

  • Include JC70 in panels with other endothelial and tumor markers for comprehensive phenotyping

• Single-cell RNA sequencing applications:

  • Use JC70 for index sorting prior to scRNA-seq to correlate protein expression with transcriptome

  • Implement CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing) with oligonucleotide-tagged JC70

  • Validate correlation between CD31 protein detection and PECAM1 transcript levels

• Spatial transcriptomics integration:

  • Combine JC70 immunofluorescence with spatial transcriptomics methods

  • Correlate spatial protein expression with gene expression patterns

  • Develop computational methods to integrate protein and RNA data in spatial contexts

• Microfluidic applications:

  • Conjugate JC70 to microfluidic channels for selective endothelial cell capture

  • Optimize flow rates and surface chemistry for maximum capture efficiency

  • Develop protocols for downstream molecular analysis of captured cells

As mentioned in search result , isolation of high-quality single cells followed by proper wash steps and blocking are essential for reliable antibody-based cell analysis.

What are the emerging modifications to antibodies like JC70 that enhance their research utility?

Emerging modifications to enhance research utility of antibodies like JC70 include:

• Conjugation advances:

  • Site-specific conjugation technologies that preserve antigen-binding regions

  • Photocleavable linkers allowing antibody release after cell identification

  • Quantum dot conjugation for increased photostability in long-term imaging

  • Enzyme conjugation for proximity-based assays (e.g., HRP, AP)

• Fragment engineering:

  • F(ab')2 and Fab fragments for reduced background in specific applications

  • Single-domain antibodies derived from JC70's variable regions

  • Bispecific formats combining JC70 with other markers for dual targeting

  • Nanobody adaptation for improved tissue penetration

• Functional modifications:

  • pH-responsive antibody variants for improved internalization studies

  • Temperature-sensitive antibodies for controlled binding/release experiments

  • Light-activatable antibodies for spatiotemporal control of binding

• Stability enhancements:

  • Humanization of mouse-derived antibodies like JC70 for improved stability

  • Deglycosylation to reduce heterogeneity and improve batch consistency

  • Pegylation for extended half-life in certain applications

• Emerging applications:

  • DNA-barcoded JC70 for spatial mapping of endothelial cells

  • Antibody-oligonucleotide conjugates for proximity ligation assays

  • Incorporation into biodegradable nanoparticles for controlled release

  • Integration with CRISPR-based systems for targeted molecular modification

These modifications align with broader trends in antibody engineering described in search result , which discusses approaches to "increase the likelihood of discovering target-specific antibodies that also have favorable physicochemical properties" and "rational co-optimization of multiple antibody features."

How does CD70 antibody research methodology differ from approaches used with JC70?

The research methodologies for CD70 antibodies differ from JC70 in several important aspects:

• Target characteristics and expression patterns:

  • CD70 (TNFSF7) is a type II transmembrane receptor normally expressed on a subset of B, T, and NK cells, where it plays a costimulatory role in immune cell activation

  • CD70 has been identified at high levels in renal cell carcinoma (RCC), with expression retained in metastatic tissues

  • In contrast, JC70 targets CD31, primarily expressed on endothelial cells

  • These different expression patterns necessitate distinct validation approaches

• Internalization studies:

  • CD70 antibodies demonstrate rapid internalization upon binding to CD70 on the cell surface

  • This property allows for the development of antibody-drug conjugates and toxin-conjugated therapeutic approaches

• Cytotoxicity assessment protocols:

  • These methods are specifically designed to evaluate the potential therapeutic applications of CD70 antibodies in cancer treatment

• Quantitative expression analysis:

  • This allows for precise correlation between transcript and protein levels

This comparison demonstrates how antibody research methodologies are tailored to the specific biological characteristics and potential applications of the target proteins.

What methodological lessons from broadly neutralizing antibody research can be applied to JC70 studies?

Research on broadly neutralizing antibodies (bnAbs) offers valuable methodological insights applicable to JC70 studies:

• Epitope mapping strategies:

  • Advanced epitope mapping techniques from bnAb research can be applied to precisely define JC70's binding site on CD31

  • Methods like hydrogen-deuterium exchange mass spectrometry, X-ray crystallography, and cryo-EM have revealed critical structural insights in bnAb research

  • For example, research on coronavirus bnAbs revealed that "ACE2 engagement of cell surface-expressed S, which is known to alter S conformation, increased fp.006 binding by 5.8-fold in a flow cytometry assay"

  • Similar approaches could uncover whether cellular activation states influence JC70 epitope accessibility

• Advanced antibody discovery platforms:

  • These platforms could be adapted to identify novel anti-CD31 antibodies with improved properties compared to JC70

• Cross-reactivity assessment approaches:

  • Similar panels could be developed to test JC70 and related antibodies against CD31 variants from different species or in different conformational states

• Combining computational and experimental approaches:

  • Similar approaches could identify conserved epitopes in CD31 that might yield more robust antibodies for research and diagnostic applications

• Novel antibody formats:

  • Such approaches could enhance JC70's utility by combining CD31 recognition with binding to other endothelial or tumor markers